Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7137MR)

This product GTTS-WQ7137MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7137MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13284MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ9460MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ158MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ79MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ10638MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ4133MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ2777MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ10631MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW